Skip to content
LATEST
Health

Alzheimer’s immune markers vary across 4 ancestry groups

The bioRxiv preprint points to shared blood immune patterns but different pathway signals, a caution for biomarker studies and trial grouping.

Alzheimer's immune markers vary across 4 ancestry groups

Researchers led by Yousef Mustafa associated Alzheimer’s disease with different peripheral immune-cell patterns across 4 ancestry groups in a bioRxiv preprint posted Nov. 13.

Mustafa and co-authors’ Nov. 13 bioRxiv preprint matters because the 4-group result challenges one-size-fits-all blood biomarker searches; it has not been certified by peer review.

The researchers analyzed whole blood RNA-sequencing data, which measures gene activity in blood, from non-Hispanic White, African American, Caribbean Hispanic and Peruvian cohorts. They used computational deconvolution, a method that estimates immune-cell proportions from gene-expression data.

Across the cohorts, Alzheimer’s disease was associated with lower proportions of naive B cells, CD56dim natural killer cells, B cells, intermediate monocyte I cells and double-negative T cells. It was also associated with higher proportions of neutrophils and non-classical monocytes.

The reported pattern points to a broad contrast between lymphoid depletion and myeloid expansion in blood. Lymphoid cells include B cells and natural killer cells, while myeloid cells include monocytes and neutrophils, which are involved in inflammatory responses.

The preprint also reported ancestry-specific pathway enrichment, meaning different gene-activity programs appeared more prominent in different cohorts. The listed signals included heme metabolism in African American cohorts, MYC targets in Caribbean Hispanic cohorts, interferon and inflammatory programs in non-Hispanic White cohorts, and TGF-beta and apoptosis signatures in Peruvian cohorts.

That matters for Alzheimer’s biomarker research because blood-based immune signatures may not behave uniformly across populations. If validated, the findings support including diverse ancestry data when testing biomarkers or sorting participants in clinical trials.

The study cannot show whether the immune shifts came before Alzheimer’s disease, followed the disease process or predict progression. The findings are also early because the work is a preprint and the reported associations have not gone through peer review.

The work does not mean a clinical blood test or immune-targeted treatment follows from these data. The next test is whether independent cohorts reproduce the same shared and ancestry-specific immune patterns.

Source: academic preprint, bioRxiv, Nov. 13, 2026.

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news